Download PDF
Pharmacopsychiatry 2003; 36(3): 121-123
DOI: 10.1055/s-2003-39980
Letter
© Georg Thieme Verlag Stuttgart · New York

Omeprazole Reduces Clozapine Plasma Concentrations

A Case ReportA. Frick1 , J. Kopitz2 , N. Bergemann1
  • 1Department of Psychiatry, University of Heidelberg, Germany
  • 2Institute of Pathochemistry and General Neurochemistry, University of Heidelberg, Germany
Further Information

Publication History

Received: 19.12.2001 Revised: 31.5.2002

Accepted: 1.7.2002

Publication Date:
13 June 2003 (online)

Also available at
    Permissions and Reprints

A number of interactions of the atypical antipsychotic clozapine with other drugs are well known, some of which can be attributed in part to the pharmacokinetic interactions associated with cytochrome P450 enzymes during drug metabolism. Clozapine is mainly metabolized by the cytochrome P450 isoenzyme 1A2. The proton pump inhibitor omeprazole can induce CYP1A2. We report on two patients with schizoaffective disorder who received omeprazole in addition to clozapine because of gastrointestinal complaints. Before the co-medication with omeprazole was started, the patients had been receiving clozapine for 78 and 41 days and for 40 and 8 days at a stable daily dose of 325 mg (patients 1 and 2, respectively). The co-medication with omeprazole was associated with a reduction in the plasma levels of clozapine of 41.9 % and 44.7 %, respectively, in these patients. The decrease in the plasma concentrations of clozapine in the presence of omeprazole might be due to the induction of the cytochrome P450 isoenzyme CYP1A2. If patients are receiving omeprazole as co-medication, close monitoring of plasma clozapine levels is recommended. If clozapine levels drop, the drug should be adjusted accordingly. If necessary, an alternative to omeprazole should be chosen.

References

  • 1 Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors.  Clin Pharmacokinet. 1996;  31 9-28
    CrossrefPubMedSearch in Google Scholar
  • 2 Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion.  Xenobiotica. 2001;  31 469-497
    CrossrefPubMedSearch in Google Scholar
  • 3 Edge S C, Markowitz J S, Devane C L. Clozapine drug interactions: a review of the literature.  Human Psychopharmacol. 1997;  12 5-20
    PubMedSearch in Google Scholar
  • 4 Eiermann B, Engel G, Johansson I, Zanger U M, Bertilsson L. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.  Br J Clin Pharmacol. 1997;  44 439-446
    CrossrefPubMedSearch in Google Scholar
  • 5 Fischer V, Vogels B, Maurer G, Tynes R. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cyochrome P450 2D6.  J Pharmacol Exp Ther. 1992;  260 1355-1366
    PubMedSearch in Google Scholar
  • 6 Flockhard D A. Drug interactions and the cytochrome P450 system. The role of P450 2C19.  Clin Pharmacokinet. 1995;  29 45-52
    PubMedSearch in Google Scholar
  • 7 Gaertner I, Gaertner H J, Vonthein R, Dietz K. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study.  J Clin Psychopharmacol. 2001;  21 305-310
    CrossrefPubMedSearch in Google Scholar
  • 8 Lane H Y, Jann M W, Chang Y C, Chiu C C, Huang M C, Lee S H, Chang W H. Repeated ingestion of grapefruit juice does not alter clozapine’s steady state plasma levels.  J Clin Psychiatry. 2001;  62 812-817
    CrossrefPubMedSearch in Google Scholar
  • 9 Linnet K, Olesen O V. Metabolism of clozapine by cDNA-expressed human cytochrome P450 enzymes.  Drug Metab Dispos. 1997;  25 1379-1382
    PubMedSearch in Google Scholar
  • 10 Masubuchi N, Li A P, Okazaki O. An evaluation of cytochrome P450 induction potential of pantoprazole in primary human hepatocytes.  Chem Biol Interact. 1998;  114 1-13
    CrossrefPubMedSearch in Google Scholar
  • 11 Neuhoff S, Langguth P, Dressler C, Andersson T B, Regardh C G, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.  Int J Clin Pharmacol Ther. 2000;  38 168-179
    PubMedSearch in Google Scholar
  • 12 Olesen O V, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations.  J Clin Pharmacol. 2001;  41 823-832
    CrossrefPubMedSearch in Google Scholar
  • 13 Robinson M. New generation proton pump inhibitors: overcoming the limitations of early-generation agents.  Eur J Gastroenterol Hepatol. 2001;  13 43-47
    PubMedSearch in Google Scholar
  • 14 Rost K L, Brösicke H, Brockmöller J. Increase of cytochrome P450 1A2 activity by omeprazole: Evidence by the 13C-(N-3-methyl)-caffeine breath test in poor and extensive metabolizers of S-mephenytoin.  Clin Pharmacol Ther. 1992;  52 170-180
    PubMedSearch in Google Scholar
  • 15 Rost K L, Fuhr U, Thomsen T, Zaigler M, Brockmöller J, Bohnemeier H, Roots I. Omeprazole weakly inhibits CYP1A2 activity in man.  Int J Clin Pharmacol Ther. 1999;  37 567-557
    PubMedSearch in Google Scholar
  • 16 Stevens I, Glaenz D, Krauss F, Walz G, Gaertner H J. Bedeutung des therapeutischen Drug-Monitoring im Rahmen der Rezidivprophylaxe mit Clozapin. In: Naber D, Müller-Spahn F (eds.) Leponex. Pharmakologie und Klinik eines atypischen Neuroleptikums. Berlin, Heidelberg; Springer 1999: 79-89
    Search in Google Scholar
  • 17 Weigmann H, Hiemke C. Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection.  J Chromatogr. 1992;  583 209-216
    PubMedSearch in Google Scholar

Dr. med. Dipl.-Psych. Niels Bergemann

Department of Psychiatry

Ruprecht-Karls-University of Heidelberg

Voss-Str. 4

69115 Heidelberg

Germany

Phone: +49 (0)6221/56-5411

Fax: +49 (0)6221/56-5477

Email: Niels_Bergemann@med.uni-heidelberg.de